The COMIRNATY Omicron XBB.1.5 vaccine from BioNTech SE - updated protection for the 2023-24 season
Published on 06/27/2026 at 18:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 18:42. Details in the imprint.
The COMIRNATY Omicron XBB.1.5 vaccine sits in a cooled vial, clear and almost inconspicuous, while nurses snap off vial caps and draw up booster doses for a late-evening vaccination shift in Mainz. For BioNTech SE, this updated mRNA shot is the quiet workhorse of the current COVID-19 season.
What COMIRNATY XBB.1.5 changes
The COMIRNATY Omicron XBB.1.5 vaccine is a monovalent mRNA formulation adapted to the XBB.1.5 lineage of SARS-CoV-2, replacing earlier bivalent BA.4/BA.5 boosters in many markets. It encodes the spike protein of the Omicron XBB.1.5 variant to better match circulating strains. Regulators such as the FDA and EMA cleared this version for the 2023-24 booster campaign in adults and adolescents, typically as a single 30 µg dose for most eligible people.
In practical terms, doctors like Prof. Ugur Sahin, BioNTech's co-founder and CEO, argue that strain adaptation keeps protection aligned with viral evolution, reducing symptomatic infection and severe disease in high-risk groups. For vaccination centers, the handling remains familiar: the product ships as a multi-dose vial, is stored in controlled cold-chain conditions, and requires standard dilution and administration procedures seen with earlier COMIRNATY versions.
Dosing, storage and daily use
The COMIRNATY Omicron XBB.1.5 formulation for adults and adolescents 12 years and older is supplied as a preservative-free frozen suspension that must be thawed, diluted, and used within defined time windows, typically 12 hours at room temperature after dilution. For younger age groups, BioNTech and Pfizer offer adjusted dose strengths and color-coded caps to simplify handling in pediatric settings. In a busy clinic, staff feel the rubber stopper under gloved fingertips and hear the soft hiss as air enters the vial, a routine that has become second nature after years of mRNA vaccinations.
Regulatory documents specify that the vaccine is administered intramuscularly in the deltoid muscle, with standard 0.3 ml doses for adults where approved. Pharmacovigilance data collected since rollout indicate a safety profile broadly consistent with earlier COMIRNATY formulations, with common local reactions such as injection-site pain and systemic reactions like fatigue and headache reported at similar frequencies.
Background on BioNTech SE shares
COMIRNATY Omicron XBB.1.5 remains a central revenue driver as BioNTech SE gradually shifts its pipeline focus toward oncology and next-generation infectious-disease vaccines.
Where regulators stand
The European Medicines Agency approved the XBB.1.5-adapted COMIRNATY formulation in September 2023 as an updated booster in line with recommendations from the European Centre for Disease Prevention and Control and the EMA COVID-19 task force. The decision followed a similar move by the US FDA, which cleared XBB.1.5-adapted mRNA vaccines for use in the United States in autumn 2023. In both regions, public-health authorities framed the update as a seasonal calibration rather than a radical overhaul.
Clinical and immunogenicity data reported by BioNTech and Pfizer show that the XBB.1.5-adapted booster elicits neutralizing antibody responses against XBB.1.5 and other Omicron-lineage variants that are higher than those induced by the previous BA.4/BA.5-adapted formulations. Early real-world data from surveillance programs point to maintained protection against hospitalization among older adults and those with underlying health conditions, although effectiveness against any symptomatic infection continues to be influenced by waning immunity and ongoing viral evolution.
Market role and competition
For BioNTech, COMIRNATY Omicron XBB.1.5 sits in a more crowded vaccine market than in 2021, with competing mRNA and protein-based boosters from other manufacturers vying for national contracts. Yet COMIRNATY remains one of the most widely procured COVID-19 vaccines globally, sustaining significant revenue even as total COVID-19 vaccine demand moderates compared with the peak pandemic years. Analysts following BioNTech highlight the XBB.1.5 update as a bridge product, buying time and cash flow while oncology programs in areas such as personalized cancer vaccines and bispecific antibodies mature.
All told, the company is gradually pivoting toward oncology, but COMIRNATY still anchors BioNTech's infectious-disease franchise alongside pipeline candidates for influenza and combination respiratory vaccines. For hospital buyers and public-health agencies, the familiarity of the COMIRNATY brand, the established cold-chain logistics, and the known safety profile help simplify procurement decisions compared with completely new platforms.
Context and BioNTech shares
Net-net, COMIRNATY Omicron XBB.1.5 is no longer the headline-grabbing hero of the pandemic's first years, but it remains a practical, updated booster that keeps BioNTech's mRNA technology in daily clinical use while the company invests heavily in oncology and next-wave vaccines. BioNTech SE shares (ISIN US09075V1026) trade on NASDAQ in US dollars, offering investors direct exposure to this transition from pandemic-driven revenues to a broader immunotherapy portfolio.
Key facts on COMIRNATY Omicron XBB.1.5
- Product: COMIRNATY Omicron XBB.1.5 (COVID-19 vaccine, mRNA, XBB.1.5-adapted)
- Manufacturer: BioNTech SE
- Category: B2B/Pro line - prescription-only vaccine
- Launch: 2023-09 EMA approval for EU booster use; 2023-09 FDA authorization for US booster campaign
- RRP / Price: Price per dose determined via national procurement contracts; in the US, list prices in the high double-digit US-dollar range per dose have been reported for post-government-purchase commercial supply.
- Availability: Widely available via hospital and clinic networks in the EU and US as part of national COVID-19 booster programs.
- Target group: Adults and adolescents eligible for COVID-19 booster vaccination, with specific age and risk-group indications depending on jurisdiction.
- Highlight / USP: Updated monovalent mRNA vaccine specifically adapted to the Omicron XBB.1.5 lineage, maintaining the established COMIRNATY handling and safety profile.
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
